Jean Cheung

406 total citations
15 papers, 203 citations indexed

About

Jean Cheung is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Jean Cheung has authored 15 papers receiving a total of 203 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 3 papers in Molecular Biology. Recurrent topics in Jean Cheung's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Jean Cheung is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Jean Cheung collaborates with scholars based in United States, United Kingdom and Australia. Jean Cheung's co-authors include Laura K. Bachrach, Laura M. Gandrud, Raquel Izumi, Ahmed Hamdy, William G. Wierda, Priti Patel, Sheetal Singh, John M. Pagel, John C. Byrd and Anna Schuh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Jean Cheung

14 papers receiving 198 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean Cheung United States 8 109 97 64 52 40 15 203
María-Jesús Artiga Spain 7 77 0.7× 152 1.6× 98 1.5× 74 1.4× 52 1.3× 7 243
Olivier Theisen France 6 163 1.5× 145 1.5× 39 0.6× 38 0.7× 84 2.1× 18 246
Jacqueline Maaloufová Czechia 9 74 0.7× 102 1.1× 67 1.0× 139 2.7× 42 1.1× 16 345
Chiara Lobetti Bodoni Italy 6 105 1.0× 116 1.2× 67 1.0× 31 0.6× 47 1.2× 8 194
Sujaatha Narayanan Canada 10 81 0.7× 63 0.6× 61 1.0× 67 1.3× 40 1.0× 43 272
Takaaki Chou Japan 9 63 0.6× 91 0.9× 122 1.9× 33 0.6× 68 1.7× 20 236
Takayasu Kato Japan 6 44 0.4× 94 1.0× 45 0.7× 32 0.6× 17 0.4× 25 159
Stefanie Bug Germany 9 76 0.7× 105 1.1× 46 0.7× 92 1.8× 46 1.1× 10 247
María García‐Álvarez Spain 9 98 0.9× 101 1.0× 58 0.9× 151 2.9× 45 1.1× 25 307
Veronika Navrkalová Czechia 8 121 1.1× 97 1.0× 47 0.7× 85 1.6× 61 1.5× 18 217

Countries citing papers authored by Jean Cheung

Since Specialization
Citations

This map shows the geographic impact of Jean Cheung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Cheung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Cheung more than expected).

Fields of papers citing papers by Jean Cheung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Cheung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Cheung. The network helps show where Jean Cheung may publish in the future.

Co-authorship network of co-authors of Jean Cheung

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Cheung. A scholar is included among the top collaborators of Jean Cheung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Cheung. Jean Cheung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Gulrajani, Michael, Jean Cheung, Fanny Krantz, et al.. (2023). P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF). HemaSphere. 7(S3). e41702a0–e41702a0. 1 indexed citations
2.
3.
Cheung, Jean, Fanny Krantz, Michael Gulrajani, et al.. (2023). P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF). HemaSphere. 7(S3). e281417f–e281417f.
4.
Zhou, Diansong, Hua Wei, Jean Cheung, et al.. (2022). Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British Journal of Clinical Pharmacology. 88(8). 3716–3729. 8 indexed citations
5.
Sharma, Shringi, Xavier Pépin, Jean Cheung, et al.. (2022). Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British Journal of Clinical Pharmacology. 88(10). 4573–4584. 3 indexed citations
6.
Elgamal, Sara, Michael Gulrajani, Jean Cheung, et al.. (2022). Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies. Blood. 140(Supplement 1). 5936–5938. 1 indexed citations
7.
Eyre, Toby A., Anna Schuh, William G. Wierda, et al.. (2021). Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study. The Lancet Haematology. 8(12). e912–e921. 40 indexed citations
8.
Cheung, Jean, Michael Gulrajani, Erika M. Gaglione, et al.. (2020). Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research. 26(12). 2800–2809. 21 indexed citations
9.
Бибикова, Елена, Brian K. Law, Jean Cheung, et al.. (2019). High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 134(Supplement_1). 2571–2571. 1 indexed citations
10.
Dyer, Martin J.S., Sven de Vos, Jia Ruan, et al.. (2018). Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 36(15_suppl). 7547–7547. 12 indexed citations
11.
12.
Fowler, Nathan, Morton Coleman, Don A. Stevens, et al.. (2018). Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).. Journal of Clinical Oncology. 36(15_suppl). 7549–7549. 15 indexed citations
13.
Patel, Viralkumar, Betty Lamothe, Mary Ayres, et al.. (2017). Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 32(4). 920–930. 27 indexed citations
14.
Mooso, Benjamin A., Ruth L. Vinall, Clifford G. Tepper, et al.. (2012). Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocrine Related Cancer. 19(6). 759–777. 35 indexed citations
15.
Gandrud, Laura M., et al.. (2003). Low-dose Intravenous Pamidronate Reduces Fractures in Childhood Osteoporosis. Journal of Pediatric Endocrinology and Metabolism. 16(6). 887–92. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María-Jesús Artiga Breakdown of academic impact, for papers by Olivier Theisen Breakdown of academic impact, for papers by Jacqueline Maaloufová Breakdown of academic impact, for papers by Chiara Lobetti Bodoni Breakdown of academic impact, for papers by Sujaatha Narayanan Breakdown of academic impact, for papers by Takaaki Chou Breakdown of academic impact, for papers by Takayasu Kato Breakdown of academic impact, for papers by Stefanie Bug Breakdown of academic impact, for papers by María García‐Álvarez Breakdown of academic impact, for papers by Veronika Navrkalová
Rankless by CCL
2026